GNF Publications
GNF Publications

GNF remains committed to the public dissemination of the results of its fundamental research programs through timely scientific publication as well as open access to many of its most signficant tools and databases.  Listed below are representative samples of recent GNF publications.


Please click here for a full list of GNF's publications.

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S,Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA.
Cancer Discov. 2014 Mar;

Discovery of Trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as Potent, Orally Bioavailable TGR5 (GPBAR1) Agonists: Structure-Activity Relationships, Lead Optimization and Chronic In Vivo Efficacy.
Phillips DP, Gao W, Yang Y, Zhang G, Lerario IK, Lau TL, Jiang J, Wang X, Nguyen DG, Bhat BG, Trotter C, Sullivan H, Welzel G, Landry J, Chen Y, Joseph SB, Li C, Gordon WP, Richmond W, Johnson K, Bretz A, Bursulaya B, Pan S, McNamara P, Seidel HM.
J Med Chem. 2014 Mar;

Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39.
Bassilana F, Carlson A, Dasilva JA, Grosshans B, Vidal S, Beck V, Wilmeringwetter B, Llamas LA, Showalter TB, Rigollier P, Bourret A, Ramamurthy A, Wu X, Harbinski F, Plonsky S, Lee L, Ruffner H, Grandi P, Schirle M, Jenkins J, Sailer AW, Bouwmeester T, Porter JA, Myer V, Finan PM, Tallarico JA, Kelleher JF 3rd, Seuwen K, Jain RK, Luchansky SJ.
Nat Chem Biol. 2014 Mar;

Identification of pathogen genomic variants through an integrated pipeline.
Manary MJ, Singhakul SS, Flannery EL, Bopp SE, Corey VC, Bright AT, McNamara CW, Walker JR, Winzeler EA.
BMC Bioinformatics. 2014 Mar; 15: 63.

Alveolar macrophages infected with Ames or Sterne strain of Bacillus anthracis elicit differential molecular expression patterns.
Langel FD, Chiang CY, Lane D, Kenny T, Ojeda JF, Zhong Y, Che J, Zhou Y, Ribot W, Kota KP, Bavari S, Panchal RG.
PLoS One. 2014 ; 9(2)

In vivo discovery of immunotherapy targets in the tumour microenvironment.
Zhou P, Shaffer DR, Alvarez Arias DA, Nakazaki Y, Pos W, Torres AJ, Cremasco V, Dougan SK, Cowley GS, Elpek K, Brogdon J, Lamb J, Turley SJ, Ploegh HL, Root DE, Love JC, Dranoff G, Hacohen N, Cantor H, Wucherpfennig KW.
Nature. 2014 Feb; 506(7486): 52-7.

Mass spectrometric analysis of citrullinated type II collagen reveals new citrulline-specific autoantibodies, which bind to human arthritic cartilage.
Haag S, Schneider N, Mason DE, Tuncel J, Andersson IE, Peters EC, Burkhardt H, Holmdahl R.
Arthritis Rheumatol. 2014 Jan;

Inhibition of c-Kit is not required for reversal of hyperglycemia by imatinib in NOD mice.
Lau J, Zhou Q, Sutton SE, Herman AE, Schmedt C, Glynne R.
PLoS One. 2014 ; 9(1)

Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model.
Vecchi S, Bufali S, Uno T, Wu T, Arcidiacono L, Filippini S, Rigat F, O'Hagan D.
Eur J Pharm Biopharm. 2014 Jan;

A biochemical screen for GroEL/GroES inhibitors.
Johnson SM, Sharif O, Mak PA, Wang HT, Engels IH, Brinker A, Schultz PG, Horwich AL, Chapman E.
Bioorg Med Chem Lett. 2014 Feb; 24(3): 786-9.